High-dose chemotherapy for high-risk primary breast cancer: an on-site review of the Bezwoda study.
Weiss, R. B.; Rifkin, R. M.; Stewart, F. M.; Theriault, R. L.; Williams, L. A.; Herman, A. A., and Beveridge,R. A. Lancet. 355(9208):999-1003, 2000 Mar 18.

Long-term quality of life in premenopausal women with node-negative localized breast cancer treated with or without adjuvant chemotherapy.
Joly, F.; Espie, M.; Marty, M.; Heron, J. F., and Henry-Amar, M.(Reprint available from: Joly F Ctr Francois Baclesse, Serv Rech Clin Route Lion MerF-14076 Caen 5 France). British Journal of Cancer. 83(5):577-582, 2000 Sep.

Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma
Hortobagyi, G. N.; Buzdar, A. U.; Theriault, R. L.; Valero, V.; Frye, D.; Booser, D. J.; Holmes,F. A.; Giralt, S.; Khouri, I.; Andersson, B.; Gajewski, J. L.; Rondon, G.; Smith, T. L.; Singletary,S. E.; Ames, F. C.; Sneige, N.; Strom, E. A.; McNeese, M. D.; Deisseroth, A. B., and Champlin,R. E. (Reprint available from: Hortobagyi GN Univ Texas, MD Anderson Canc Ctr, Dept Breast MedOncol 1515 Holcombe Blvd,Box 56 Houston, TX 77030 USA)..Journal of the National Cancer Institute. 92(3):225-233, 2000 Feb 2.

Safety and efficacy results of a randomized trial comparing adjuvant toremifene and tamoxifen in postmenopausal patients with node-positive breast cancer.
Holli, K.; Valavaara, R.; Blanco, G.; Kataja, V.; Hietanen, P.; Flander, M.; Pukkala, E.,and Joensuu, H.. Journal of Clinical Oncology. 18(20):3487-3494, 2000 Oct 15.

Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: The International Breast Cancer Study Group Trial VII.
Crivellari, D.; Bonetti, M.; Castiglione-Gertsch, M.; Gelber, R. D.; Rudenstam, C. M.; Thurlimann,B.; Price, K. N.; Coates, A. S.; Hurny, C.; Bernhard, J.; Lindtner, J.; Collins, J.; Senn, H. J.;Cavalli, F.; Forbes, J.;Gudgeon, A.; Simoncini, E.; Cortes-Funes, H.; Veronesi, A.; Fey, M.,and Goldhirsch, A.. Journal of Clinical Oncology. 18(7):1412-1422, 2000 Apr.

Early start of adjuvant chemotherapy may improve treatment outcome for premenopausal breast cancer patients with tumors not expressing estrogen receptors.
Colleoni, M.; Bonetti, M.; Coates, A. S.; Castiglione-Gertsch, M.; Gelber, R. D.; Price, K.; Rudenstam, C. M.;Lindtner, J.; Collins, J.; Thurlimann, B.; Holmberg, S.; Veronesi, A.; Marini, G., and Goldhirsch,A. Journal of Clinical Oncology. 18(3):584-590, 2000 Feb.

Increased risk of acute leukemia after adjuvant chemotherapy for breast cancer: A population-based study.
Chaplain, G.; Milan, C.; Sgro, C.; Carli, P. M., and Bonithon-Kopp, C. Journal of Clinical Oncology.18(15):2836-2842, 2000 Aug.

Quality of life after adjuvant chemotherapy for breast cancer.
Broeckel, J. A.; Jacobsen, P. B.; Balducci, L.; Horton, J., and Lyman, G. H. Breast Cancer Research & Treatment. 62(2):141-150, 2000 Jul.

Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients
Baun, S.; Kentenich, C.; Janni, W.; Hepp, F.; de Waal, J.; Willgeroth, F.; Sommer, H., and Pantel, K.. Journal of Clinical Oncology. 18(1):80-86, 2000 Jan.

Feasibility of a dose-intensive CMF regimen with granulocyte colony-stimulating factor as adjuvant therapy in premenopausal patients with node-positive breast cancer.
Bos, A. M. E.; de Graaf, H.; de Vries, E. G. E.; Piersma, H., and Willemse, P. H. B. (Reprint available from: Bos AME Univ Groningen Hosp, Div Med Oncol, Dept Internal Med POB 30 001 NL-9700 RB Groningen Netherlands).. British Journal of Cancer. 82(12):1920-1924, 2000 June

Disease-free survival advantage of adjuvant cyclophosphamide, methotrexate, and fluorouracil in patients with node-negative, rapidly proliferating breast cancer: A randomized multicenter study.
Amadori, D.; Nanni, O.; Marangolo, M.; Pacini, P.; Ravaioli, A.; Rossi, A.; Gambi, A.; Catalano, G.; Perroni, D.; Scarpi, E.; Giunchi, D. C.; Tienghi, A.; Becciolini, A., and Volpi, A. Journal of Clinical Oncology. 18(17):3125-3134, 2000 Sep.

Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer?
Aebi, S.; Gelber, S.; Castiglione-Gertsch, M.; Gelber, R. D.; Collins, J.; Thurlimann, B.; Rudenstam, C. M.; Lindtner, J.; Crivellari, D.; Cortes-Funes, H.; Simoncini, E.; Werner, I. D.; Coates, A. S., and Goldhirsch, A. Lancet. 355(9218):1869-1874, 2000 May 27.

Randomized 2 x 2 trial evaluating hormonal treatment and the duration of chemotherapy in node-positive breast cancer patients: An update based on 10 years' follow-up.
Sauerbrei, W.; Bastert, G.; Bojar, H.; Beyerle, C.; Neumann, R. L. A.; Schmoor, C., and Schumacher, M.. Journal of Clinical Oncology. 18(1):94-101, 2000 Jan.

Framing of outcome and probability of recurrence: Breast cancer patients' choice of adjuvant chemotherapy (ACT) in hypothetical patient scenarios.
Zimmermann, C.; Baldo, C., and Molino, A. Breast Cancer Research & Treatment. 60(1):9-14, 2000 Mar

Primary systemic therapy in operable breast cancer
Wolff, A. C. and Davidson, N. E.. Journal of Clinical Oncology. 18(7):1558-1569, 2000 Apr.

What threshold for adjuvant therapy in older breast cancer patients?
Extermann, M.; Balducci, L., and Lyman, G. H. Journal of Clinical Oncology.18(8):1709-1717, 2000 Apr.

Bisphosphonates in the adjuvant treatment of cancer: experimental evidence and first clinical results [Review].
Diel, I. J. and Mundy, G. R. (Reprint available from: Diel IJ Univ Heidelberg,Dept Ob Gyn Voss Str 9 D-69115 Heidelberg Germany). British Journal of Cancer. 82(8):1381-1386, 2000 Apr.

Concurrent adjuvant chemotherapy and immediate breast reconstruction with skin expanders after mastectomy for breast cancer.
Caffo, O.; Cazzolli, D.; Scalet, A.; Zani, B.; Ambrosini, G.; Amichetti, M.; Bernardi, D.; Brugnara, S.;Ciaghi, G.; Lucenti, A.; Natale, N.; Agugiaro, S.; Eccher, C., and Galligioni, E. Breast Cancer Research & Treatment. 60(3):267-275, 2000 Apr

Cognitive function in breast cancer patients receiving adjuvant chemotherapy.
Brezden, C. B.; Phillips, K. A.; Abdolell, M.; Bunston, T., and Tannock, I. F. Journal of Clinical Oncology. 18(14):2695-2701, 2000 Jul.

Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients: Results of the Italian Breast Cancer Adjuvant Study Group 02 Randomized Trial.
Boccardo, F.; Rubagotti, A.; Amoroso, D.; Mesiti, M.; Romeo, D.; Sismondi, P.; Giai, M.; Genta, F.; Pacini, P.; Distante, V.; Bolognesi, A.; Aldrighetii, D., and Farris, A.. Journal of Clinical Oncology. 18(14):2718-2727, 2000 Jul.

Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial.
Bergh, J.; Wiklund, T.; Erikstein, B.; Lidbrink, E.; Lindman, H.; Malmstrom, P.; Kellokumpu-Lehtinen, P.; Bengtsson, N. O.; Soderlund, G.; Anker, G.; Wist, E.; Ottosson, S.; Salminen, E.; Ljungman, P.; Holte, H.; Nilsson, J.; Blomqvist, C., and Wilking, N.. Lancet. 356(9239):1384-1391, 2000 Oct 21

Taxanes as adjuvant for breast cancer.
Goldhirsch, A.; Francis, P.; Castiglione-Gertsch, M.; Gelber, R. D., and Coates, A. S. (Reprint available from: Goldhirsch A European Inst Oncol, Int Breast Canc Study Grp I-20141 Milan Italy).. Lancet. 356(9228):507-508, 2000 Aug 5. No abstract

Top of Page